Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
British Journal of Cancer|January 13, 2016
c-Rel and its many roles in cancer: an old story with new twistsJill E Hunter, Jack Leslie, Neil D Perkins
Scientific Reports|May 13, 2022
Increased migration and motility in XIAP-null cells mediated by the C-RAF protein kinaseLauren G Russell, Lydia A K Davis, Jill E Hunter, et al.
Communications Biology|December 9, 2021
Centrosome dysfunction associated with somatic expression of the synaptonemal complex protein TEX12Sumit Sandhu, Ieng F Sou, Jill E Hunter, et al.
Cancers|October 14, 2023
Expression and Activity of the NF-κB Subunits in Chronic Lymphocytic Leukaemia: A Role for RelB and Non-Canonical SignallingEvan A Mulligan, Susan J Tudhope, Jill E Hunter, et al.
The Biochemical Journal|October 14, 2022
Claspin haploinsufficiency leads to defects in fertility, hyperplasia and an increased oncogenic potentialSuzanne Madgwick, Saimir Luli, Helene Sellier, et al.
The Biochemical Journal|October 14, 2022
Up-regulation of the PI3K/AKT and RHO/RAC/PAK signalling pathways in CHK1 inhibitor resistant Eµ-Myc lymphoma cellsJill E Hunter, Amy E Campbell, Scott Kerridge, et al.
Oncotarget|November 6, 2015
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemiaAshleigh Herriott, Susan J Tudhope, Gesa Junge, et al.
Hepatology (Baltimore, Md.)|September 11, 2022
c-Rel-dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesisJack Leslie, Jill E Hunter, Amy Collins, et al.
The Biochemical Journal|October 14, 2022
Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathwayJill E Hunter, Amy E Campbell, Nicola L Hannaway, et al.
Oncotarget|August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphomaMike I Walton, Paul D Eve, Angela Hayes, et al.
Pageof 1